Keros Therapeutics Inc (KROS)
45.64
-0.85
(-1.83%)
USD |
NASDAQ |
Jun 25, 16:00
45.64
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Cash from Financing (Quarterly): 156.80M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 156.80M |
| December 31, 2023 | 69.25M |
| September 30, 2023 | 0.284M |
| June 30, 2023 | 1.74M |
| March 31, 2023 | 107.68M |
| December 31, 2022 | 61.42M |
| September 30, 2022 | 48.58M |
| June 30, 2022 | 10.19M |
| March 31, 2022 | 0.118M |
| December 31, 2021 | 28.42M |
| September 30, 2021 | 0.035M |
| Date | Value |
|---|---|
| June 30, 2021 | 0.057M |
| March 31, 2021 | 0.042M |
| December 31, 2020 | 140.12M |
| September 30, 2020 | 0.009M |
| June 30, 2020 | 100.12M |
| March 31, 2020 | 55.79M |
| December 31, 2019 | 0.004M |
| September 30, 2019 | 0.006M |
| June 30, 2019 | 0.004M |
| March 31, 2019 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.004M
Minimum
Jun 2019
156.80M
Maximum
Mar 2024
39.03M
Average
5.966M
Median
Cash from Financing (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 28.91M |
| Biomarin Pharmaceutical Inc | -42.79M |
| Sarepta Therapeutics Inc | 22.14M |
| PTC Therapeutics Inc | 0.54M |
| ADMA Biologics Inc | -1.447M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -44.56M |
| Cash from Investing (Quarterly) | -0.946M |
| Free Cash Flow | -137.18M |
| Free Cash Flow Per Share (Quarterly) | -1.275 |
| Free Cash Flow to Equity (Quarterly) | -45.51M |
| Free Cash Flow Yield | -9.61% |